Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87 million versus the consensus estimate of $73.6 million.

2017 Financial Guidance

Ironwood now expects:

• R&D expenses to be in the low-to-middle end of the previously guided $145 million to $160 million range;
• SG&A expenses to be in the low-to-middle end of the previously guided $235 million to $250 million range;
• the combined Allergan and Ironwood total 2017 marketing and sales expenses for LINZESS to be in the middle of the previously guided $250 million to $280 million range; and
• to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided.
• Ironwood continues to expect net interest expense to be approximately $40 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.